Bayer data for kidney disease hope finerenone sets up filingsBayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication Share XBayer data for kidney disease hope finerenone sets up filingshttps://pharmaphorum.com/news/bayer-data-for-kidney-disease-hope-finerenone-sets-up-filings/
Novo launches type 2 diabetes pill in UK after NICE waives reviewNovo Nordisk has launched its type 2 diabetes pill Rybelsus (semaglutide) in the UK, after cost-effectiveness watchdog NICE Share XNovo launches type 2 diabetes pill in UK after NICE waives reviewhttps://pharmaphorum.com/news/novo-launches-type-2-diabetes-pill-in-uk/
NHS backs free behavioural change app for type 2 diabeticsNHS England has awarded a contract to tech company Changing Health to develop a free app to help Share XNHS backs free behavioural change app for type 2 diabeticshttps://pharmaphorum.com/news/nhs-backs-free-behavioural-change-app-for-type-2-diabetics/
FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseaseThe FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new Share XFDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseasehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-in-chronic-kidney-disease/
Lilly, Boehringer bag FDA okay for diabetes triple Trijardy XREli Lilly and Boehringer Ingelheim’s longstanding alliance in diabetes has delivered another new product, this time a three-drug Share XLilly, Boehringer bag FDA okay for diabetes triple Trijardy XRhttps://pharmaphorum.com/news/lilly-boehringer-bag-fda-okay-for-diabetes-triple-trijardy-xr/
AZ’s Forxiga gets heart claim data on its EU labelAstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2 Share XAZ’s Forxiga gets heart claim data on its EU labelhttps://pharmaphorum.com/news/azs-forxiga-gets-heart-claim-data-on-its-eu-label/
Novo Nordisk’s Victoza gets FDA okay for paediatric useNovo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as Share XNovo Nordisk’s Victoza gets FDA okay for paediatric usehttps://pharmaphorum.com/news/novo-nordisks-victoza-fda-paediatric-use/
Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney diseaseAfter moving from academia to industry, Stephen Gough is now Novo Nordisk’s global chief medical officer, working on Share XBeyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney diseasehttps://pharmaphorum.com/r-d/views-analysis-r-d/beyond-glucose-in-type-2-diabetes-how-novo-nordisk-is-looking-to-address-chronic-kidney-disease/
Trial sets up 2020 filing for Poxel’s novel diabetes drugFrench biotech Poxel has positive phase 3 data for a new type of oral therapy for type 2 Share XTrial sets up 2020 filing for Poxel’s novel diabetes drughttps://pharmaphorum.com/news/trial-sets-up-2020-filing-for-poxels-novel-diabetes-drug/
